-transparent.png){kind=logo}
The prostaglandin endoperoxide PGH2, HHT, HETE, thromboxane A2, and thromboxane B2, which are all products of arachidonic acid metabolism of human platelets, were tested for their ability to modulate platelet cyclic nucleotide levels. None of the compounds tested altered the basal level of cAMP or cGMP, and only PGH2 and thromboxane A2 inhibited PGE1-stimulated cAMP accumulation. Thromboxane A2 was found to be a more potent inhibitor of PGE1-stimulated cAMP accumulation and inducer of platelet aggregation than PGH2.
Related Publications
O V Miller, and
R A Johnson, and
R R Gorman
November 1978,
Life sciences,
O V Miller, and
R A Johnson, and
R R Gorman
January 1980,
British journal of pharmacology,
O V Miller, and
R A Johnson, and
R R Gorman
October 1983,
Proceedings of the National Academy of Sciences of the United States of America,
O V Miller, and
R A Johnson, and
R R Gorman
January 1980,
Journal of cyclic nucleotide research,
O V Miller, and
R A Johnson, and
R R Gorman
March 1993,
European journal of pharmacology,
O V Miller, and
R A Johnson, and
R R Gorman
June 1977,
Nature,
O V Miller, and
R A Johnson, and
R R Gorman
February 1993,
The Biochemical journal,
O V Miller, and
R A Johnson, and
R R Gorman
January 1987,
Progress in clinical and biological research,
O V Miller, and
R A Johnson, and
R R Gorman
August 1978,
The American journal of gastroenterology,
O V Miller, and
R A Johnson, and
R R Gorman
January 1980,
Advances in prostaglandin and thromboxane research,
